Thomas Madden – CEO, Acuitas Therapeutics
Thomas Madden is the CEO of Acuitas Therapeutics, the lipid nanoparticle delivery technology company whose platforms underpinned some of the most significant advances in mRNA medicine, such as the COVID-19…
Acuitas is a biotechnology company that works with partners to develop new therapies to address unmet clinical needs based on our internationally recognized capabilities in delivery technology.
Contact
6190 Agronomy Road, Suite 405 Vancouver, BC, V6T 1Z3, Canada
Thomas Madden is the CEO of Acuitas Therapeutics, the lipid nanoparticle delivery technology company whose platforms underpinned some of the most significant advances in mRNA medicine, such as the COVID-19…
Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid…
Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid…
Novo Nordisk has rebranded as ‘Novo’ and plans to enter new therapeutic areas as part of CEO Maziar Mike Doustdar’s push to reinvigorate growth. The company has already reinvented itself…
The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for…
Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity…
Five conferences, anxiety spreading across five continents, one unmistakable pattern: the global pharmaceutical industry is transforming at a dizzying pace. From Philadelphia to Geneva, from Istanbul to Chicago and London,…
In debates over drug pricing, affordability and innovation are often framed as a zero-sum trade-off. Zeba M. Khan, Editor-in-Chief of ISPOR’s Value & Outcomes Spotlight, argues it doesn’t have to…
New Takeda CEO Julie Kim inherits a firm with flatlining growth and generic competition eating away at its lead drug’s revenues. Will three major new launches over the next year…
Across the Global South, hundreds of millions of people live without reliable access to basic healthcare. Too few doctors, too little data, and systems too fragile to scale. However, as…
Sally Epstein looks at why the world’s biggest AI companies are all pivoting towards biopharmaceuticals. Epstein, an entrepreneur in residence at Cambridge Innovation Capital, argues that drug discovery – if…
Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted…
Against a backdrop of rising geopolitical tension, regulatory fragmentation, and mounting pressure on Europe’s healthcare systems, Prague-headquartered Zentiva is positioning itself as a distinctly European pharmaceutical player focused on long-term…
Brendan Shaw maps the global fallout from the Trump Administration’s Most Favoured Nation drug pricing agenda. From stalled launches to rattled health ministries, Shaw argues that MFN has thrown pharmaceutical…
Jay Iyer, CEO of the Access to Medicine Foundation, warns that rising nationalism and “onshoring” risk dismantling decades of progress in global health. As geopolitical tensions reshape how drugs are…
See our Cookie Privacy Policy Here
